Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction.

Kaba NK, Francis CW, Moss AJ, Zareba W, Oakes D, Knox KL, Fernández ID, Rainwater DL; THROMBO Investigators.

J Thromb Haemost. 2004 May;2(5):718-25.

2.

Thrombogenic factors and recurrent coronary events.

Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF, Case RB.

Circulation. 1999 May 18;99(19):2517-22.

3.

Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic american Indian women: the strong heart study.

Zhang Y, Howard BV, Cowan LD, Welty TK, Schaefer CF, Wild RA, Yeh J, Lee ET.

J Womens Health (Larchmt). 2004 Mar;13(2):155-63.

PMID:
15072729
4.

Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.

Zareba W, Pancio G, Moss AJ, Kalaria VG, Marder VJ, Weiss HJ, Watelet LF, Sparks CE.

Thromb Haemost. 2001 Sep;86(3):791-9.

PMID:
11583309
6.

Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes.

Chaturvedi N, Fuller JH, Taskinen MR; EURODIAB PCS Group.

Diabetes Care. 2001 Dec;24(12):2071-7.

PMID:
11723085
7.

Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.

Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F, Ersoz HO.

Exp Clin Endocrinol Diabetes. 2008 Nov;116(10):619-24. doi: 10.1055/s-2008-1065365. Epub 2008 May 16.

PMID:
18484067
9.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
10.

Lipoprotein (a) and lipid and non-lipid risk factors in coronaries risk assessment.

Agoşton-Coldea L, Rusu LD, Zdrenghea D, Rusu ML, Pop D, Crăciun A, Poanta L, Gatfossé M, Rosenstingl S, Mocan T.

Rom J Intern Med. 2008;46(2):137-44.

PMID:
19284085
11.

Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.

Thøgersen AM, Söderberg S, Jansson JH, Dahlén G, Boman K, Nilsson TK, Lindahl B, Weinehall L, Stenlund H, Lundberg V, Johnson O, Ahrén B, Hallmans G.

Eur J Cardiovasc Prev Rehabil. 2004 Feb;11(1):33-40.

PMID:
15167204
12.

Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers.

Pineda J, Marín F, Marco P, Roldán V, Valencia J, Ruiz-Nodar JM, Sogorb F, Lip GY.

Int J Cardiol. 2009 Aug 14;136(2):222-5. doi: 10.1016/j.ijcard.2008.04.020. Epub 2008 Jul 14.

PMID:
18625524
13.
15.

A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.

Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS.

Clin Ther. 2007 Jul;29(7):1403-14.

PMID:
17825691
16.

Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).

Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.

Am J Cardiol. 2009 Jan 1;103(1):41-5. doi: 10.1016/j.amjcard.2008.08.033. Epub 2008 Oct 10.

PMID:
19101227
17.

Pharmacologic treatment of type 2 diabetic dyslipidemia.

Moon YS, Kashyap ML.

Pharmacotherapy. 2004 Dec;24(12):1692-713. Review.

PMID:
15585439
18.

Serum lipid levels for a multicultural population in Auckland, New Zealand: results from the Diabetes Heart and Health Survey (DHAH) 2002-2003.

Gentles D, Metcalf P, Dyall L, Scragg R, Sundborn G, Schaaf D, Black PN, Jackson RT.

N Z Med J. 2007 Nov 9;120(1265):U2800.

PMID:
18264180
19.

Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapy.

Jonkers IJ, de Man FH, van Tilburg NH, van der Laarse A, Sandset PM, Smelt AH, Bertina RM.

Blood Coagul Fibrinolysis. 2001 Dec;12(8):705-12.

PMID:
11734672
20.

Associations of leisure-time physical activity and obesity with atherogenic lipoprotein-lipid markers among non-smoking middle-aged men.

Carroll S, Cooke CB, Butterly RJ, Gately P.

Scand J Med Sci Sports. 2001 Feb;11(1):38-46.

PMID:
11169234

Supplemental Content

Support Center